Clara N Curiel-Lewandrowski, MD

Interim Director of Research, Cancer Center

Co-Director, Skin Cancer Institute, Cancer Center

Professor, Medicine, College of Medicine (Dermatology)

Chief, Division of Dermatology, Department of Medicine

Program Director, Dermatology Residency Program

The Alan and Janice Levin Family Endowed Chair for Excellence in Cancer Research

Photo of Dr. Clara Curiel-Lewandrowski smiling.

ccuriel@arizona.edu

Links

Department Profile

NCBI Bibliography

Dr. Curiel-Lewandrowski's role as a member of the UACC is to establish and foster research activities related to the skin cancer field across multiple disciplines. She is currently the Co-Director of the Skin Cancer Institute and Director of the Cutaneous Oncology Program. She has served as a lead dermatologist in seven clinical studies and as a PI in seven clinical trials through the PO1-Skin Cancer Chemoprevention Grant, the UA NCI/DCP/Cancer Chemoprevention Consortium Agreement, and sponsored studies. She has been instrumental in establishing research collaborations between the UACC and the College of Optical Sciences, Bioengineering, and the Department of Radiology to evaluate novel imaging modalities in the skin cancer arena.

Cancer Focus

To date, her research interests has focused in photobiology, early skin cancer detection, and primary prevention.

Research Program Role

Cancer Prevention and Control Program

Display Name

Clara N Curiel-Lewandrowski, MD

Publications

Low-cost, high-speed near infrared reflectance confocal microscope.

Gong C, Kulkarni N, Zhu W, Nguyen CD, Curiel-Lewandrowski C, Kang D. 2019. Low-cost, high-speed near infrared reflectance confocal microscope. Biomed Opt Express. 10:3497–3505. doi:10.1364/BOE.10.003497.

Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials.

Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, et al. 2019. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 125:18–44. doi:10.1002/cncr.31719.

Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma.

Almutairi AR, Alkhatib NS, Oh M, Curiel-Lewandrowski C, Babiker HM, Cranmer LD, McBride A, Abraham I. 2019. Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma. JAMA Dermatol. 155:22–28. doi:10.1001/jamadermatol.2018.3958.

Guidelines of care for the management of primary cutaneous melanoma.

Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, Gershenwald JE, Guild V, Grant-Kels JM, Halpern AC, Johnson TM, et al. 2019. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 80:208–250. doi:10.1016/j.jaad.2018.08.055.

Staging Systems to Predict Metastatic Cutaneous Squamous Cell Carcinoma: Unsatisfactory for Clinical Use, but Some Less So?

Abraham I, Curiel-Lewandrowski C. 2018. Staging Systems to Predict Metastatic Cutaneous Squamous Cell Carcinoma: Unsatisfactory for Clinical Use, but Some Less So?. JAMA Dermatol. 154:1391–1392. doi:10.1001/jamadermatol.2018.3940.

Potential Underuse of the Sentinel Lymph Node Biopsy for High-Risk Squamous Cell Carcinoma of the Skin.

Glazer AM, Stratton D, Curiel-Lewandrowski C. 2018. Potential Underuse of the Sentinel Lymph Node Biopsy for High-Risk Squamous Cell Carcinoma of the Skin. JAMA Dermatol. 154:972–973. doi:10.1001/jamadermatol.2018.1807.

Pharmacological TLR4 Antagonism Using Topical Resatorvid Blocks Solar UV-Induced Skin Tumorigenesis in SKH-1 Mice.

Blohm-Mangone K, Burkett NB, Tahsin S, Myrdal PB, Aodah A, Ho B, Janda J, McComas M, Saboda K, Roe DJ, et al. 2018. Pharmacological TLR4 Antagonism Using Topical Resatorvid Blocks Solar UV-Induced Skin Tumorigenesis in SKH-1 Mice. Cancer Prev Res (Phila). 11:265–278. doi:10.1158/1940-6207.CAPR-17-0349.

Protein activation mapping of human sun-protected epidermis after an acute dose of erythemic solar simulated light.

Einspahr JG, Curiel-Lewandrowski C, Calvert VS, Stratton SP, Alberts DS, Warneke J, Hu C, Saboda K, Wagener EL, Dickinson S, et al. 2017. Protein activation mapping of human sun-protected epidermis after an acute dose of erythemic solar simulated light. NPJ Precis Oncol. 1. doi:10.1038/s41698-017-0037-7.

Inhibition of Akt Enhances the Chemopreventive Effects of Topical Rapamycin in Mouse Skin.

Dickinson SE, Janda J, Criswell J, Blohm-Mangone K, Olson ER, Liu Z, Barber C, Petricoin EF, Calvert VS, Einspahr J, et al. 2016. Inhibition of Akt Enhances the Chemopreventive Effects of Topical Rapamycin in Mouse Skin. Cancer Prev Res (Phila). 9:215–24. doi:10.1158/1940-6207.CAPR-15-0419.

Resatorvid-based Pharmacological Antagonism of Cutaneous TLR4 Blocks UV-induced NF-κB and AP-1 Signaling in Keratinocytes and Mouse Skin.

Janda J, Burkett NB, Blohm-Mangone K, Huang V, Curiel-Lewandrowski C, Alberts DS, Petricoin EF, Calvert VS, Einspahr J, Dong Z, et al. 2016. Resatorvid-based Pharmacological Antagonism of Cutaneous TLR4 Blocks UV-induced NF-κB and AP-1 Signaling in Keratinocytes and Mouse Skin. Photochem Photobiol. 92:816–825. doi:10.1111/php.12659.

Clara N Curiel-Lewandrowski, MD

Links

Cancer Focus

Display Name Clara N Curiel-Lewandrowski, MD

Publications

Display Name

Clara N Curiel-Lewandrowski, MD